The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products. Its lead program MGX-001 targets hemophilia A with clinical development targeted for 2026.
Cyborg Score Rationale
According to 4 analysts, the average rating for MGX stock is "Strong Buy" with a 12-month stock price target of $9.25, which is an increase of 508.55% from the latest price. However, early-stage losses and cash burn remain key risks for this pre-commercial biotech company.
Top Insights
Lead program MGX-001 for hemophilia A showed sustained Factor VIII activity in nonhuman primates with durable response through ~19 months
Recently renamed to Metagenomi Therapeutics (Feb 2026) reflecting strategic focus on later-stage preclinical assets
Pre-IND meeting held in Q4 2025 positioning for clinical trial entry in 2026
Analyst consensus targets 508% upside from current levels, indicating significant market skepticism on current valuation
Named Competitors
Caribou Biosciences — In vivo gene editing for hemophilia and other genetic disorders
Prime Medicine — Prime editing platform for genetic medicine